Zoetis is trading at $69.27 (-5.64%) after management highlighted softer companion-animal demand and tougher competition.
- At the September 14 Morgan Stanley healthcare conference, executives described near-term pressure but emphasized longer-term pipeline opportunities.
- Broader weakness contributed, with the S&P 500 down 0.36% and NASDAQ down 0.78% amid elevated Treasury yields and pre-Fed caution.
- Company-specific pressure appears more significant than the moderate market decline; no new September 15 earnings release was identified.